All In Biotech

Drug Trial Radar · NCT03289962

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors

Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

273

Actual

Start

Dec 21, 2017

Primary completion

Jul 1, 2025

Study completion Jul 1, 2025

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
BioNTech SE
First posted
Sep 21, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 \[anti-PD-L1\] antibody).

Conditions

  • Melanoma
  • Non-Small Cell Lung Cancer
  • Bladder Cancer
  • Colorectal Cancer
  • Triple Negative Breast Cancer
  • Renal Cancer
  • Head and Neck Cancer
  • Other Solid Cancers

Interventions

  • Autogene cevumeranDrug

    Autogene cevumeran will be administered by intravenous (IV) infusion, in 21-day cycles.

  • AtezolizumabDrug

    Atezolizumab will be administered by IV infusion on Day 1 of every 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Dose-Limiting Toxicities (DLTs)Time frame: Phase 1a: Days 1 to 14 / Phase 1b: Days 1 to 21
  2. MTD/Recommended Phase 2 Dose (RP2D) of Autogene CevumeranTime frame: Phase 1a: Days 1 to 14 / Phase 1b: Days 1 to 21
  3. Percentage of Participants with Adverse Events (AEs)Time frame: Baseline up to end of the study (up to approximately 3 years)
  4. Percentage of Participants with Immune-Mediated Adverse Events (imAEs)Time frame: Baseline up to end of the study (up to approximately 3 years)
  5. Percentage of Participants by Number of Treatment Cycles ReceivedTime frame: Baseline up to end of the study (up to approximately 3 years)
  6. Dose Intensity of Autogene CevumeranTime frame: Baseline up to end of the study (up to approximately 3 years)
  7. Change from Baseline in Targeted Vital SignsTime frame: Baseline up to end of study (up to approximately 3 years)
  8. Change from Baseline in Targeted Clinical Laboratory Test ResultsTime frame: Baseline up to end of study (up to approximately 3 years)
  9. Change from Baseline in ECGsTime frame: Baseline up to end of study (up to approximately 3 years)

Locations

33 sites in 8 countries. Site status is shown where the registry gives one.

  • HonorHealth Research Institute ? Bisgrove

    Scottsdale, Arizona

  • The Los Angeles Clinic

    Los Angeles, California

  • UCSF Comprehensive Cancer Ctr

    San Francisco, California

  • Stanford Cancer Center

    Stanford, California

  • University of Colorado

    Aurora, Colorado

  • Yale University Cancer Center, Smilow Cancer Hospital

    New Haven, Connecticut

  • Massachusetts General Hospital.

    Boston, Massachusetts

  • Dana Farber Can Ins

    Boston, Massachusetts

  • Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley

    Las Vegas, Nevada

  • Columbia University Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • Providence Oncology and Hematology Care Eastside

    Portland, Oregon

  • Sarah Cannon Res Inst

    Nashville, Tennessee

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • UZ Gent

    Ghent, Belgium

  • CHU de Liège (Sart Tilman)

    Liège, Belgium

  • ZAS Sint Augustinus Wilrijk

    Wilrijk, Belgium

  • The Ottawa Hospital Cancer Centre

    Ottawa, Ontario, Canada

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada

  • Universitätsklinikum Essen

    Essen, Germany

  • Nationales Centrum für Tumorerkrankungen Heidelberg (NCT)

    Heidelberg, Germany

  • Fachklinik für Lungenerkrankungen

    Immenhausen, Germany

  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz

    Mainz, Germany

  • Antoni van Leeuwenhoek Ziekenhuis

    Amsterdam, Netherlands

  • Universitair Medisch Centrum Utrecht

    Utrecht, Netherlands

  • Vall d?Hebron Institute of Oncology (VHIO), Barcelona

    Barcelona, Spain

  • Clinica Universitaria de Navarra

    Pamplona, Navarre, Spain

  • Karolinska Universitetssjukhuset, Solna

    Stockholm, Sweden

  • Akademiska sjukhuset, Onkologkliniken

    Uppsala, Sweden

  • Barts Health NHS Trust - St Bartholomew's Hospital

    London, United Kingdom

  • Southampton General Hospital

    Southampton, United Kingdom

  • The Royal Marsden Hospital

    Sutton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.